Bullous Sweet's syndrome in congenital neutropenia: association with pegfilgrastim

J Am Acad Dermatol. 2005 May;52(5):901-5. doi: 10.1016/j.jaad.2004.12.028.

Abstract

Sweet's syndrome is an acute febrile neutrophilic dermatosis marked by attacks of painful, plaque-forming inflammatory papules accompanied by fever, arthralgias, peripheral leukocytosis, a diffuse dermal neutrophilic infiltrate, and prompt resolution of symptoms and lesions with glucocorticoid therapy. There are many reports of drug-induced Sweet's syndrome to various medications including all- trans -retinoic acid, carbamazepine, hydralazine, levonorgestrel/ethinyl estradiol, minocycline, trimethoprim/sulfamethoxazole, and granulocyte colony-stimulating factor. We describe the first known case of Sweet's syndrome induced by pegfilgrastim, a pegylated form of granulocyte colony-stimulating factor with unique pharmacologic properties that may induce Sweet's syndrome in patients with no history of neutrophilic dermatoses associated with granulocyte colony-stimulating factor therapy.

Publication types

  • Case Reports

MeSH terms

  • Blister / chemically induced*
  • Blister / drug therapy
  • Filgrastim
  • Granulocyte Colony-Stimulating Factor / adverse effects*
  • Granulocyte Colony-Stimulating Factor / therapeutic use
  • Humans
  • Leukocyte Count
  • Male
  • Middle Aged
  • Neutropenia / congenital*
  • Neutropenia / drug therapy
  • Neutrophils / cytology
  • Polyethylene Glycols
  • Recombinant Proteins
  • Sweet Syndrome / chemically induced*

Substances

  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • pegfilgrastim
  • Polyethylene Glycols
  • Filgrastim